Annual SGA
$34.83 M
+$7.31 M+26.55%
December 31, 2023
Summary
- As of February 8, 2025, KROS annual SGA is $34.83 million, with the most recent change of +$7.31 million (+26.55%) on December 31, 2023.
- During the last 3 years, KROS annual SGA has risen by +$22.04 million (+172.20%).
- KROS annual SGA is now at all-time high.
Performance
KROS SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$9.82 M
-$141.00 K-1.42%
September 30, 2024
Summary
- As of February 8, 2025, KROS quarterly SGA is $9.82 million, with the most recent change of -$141.00 thousand (-1.42%) on September 30, 2024.
- Over the past year, KROS quarterly SGA has increased by +$715.00 thousand (+7.85%).
- KROS quarterly SGA is now -4.73% below its all-time high of $10.31 million, reached on March 31, 2024.
Performance
KROS Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$1.80 B
-$181.57 M-11.23%
September 30, 2024
Summary
- As of February 8, 2025, KROS TTM SGA is -$1.80 billion, with the most recent change of -$181.57 million (-11.23%) on September 30, 2024.
- Over the past year, KROS TTM SGA has dropped by -$1.83 billion (-5263.11%).
- KROS TTM SGA is now -9052.75% below its all-time high of -$19.65 million.
Performance
KROS TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
KROS Selling, General & Administrative Expenses Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +26.6% | +7.8% | -5263.1% |
3 y3 years | +172.2% | +83.0% | -9608.9% |
5 y5 years | +2104.7% | +910.3% | -10000.0% |
KROS Selling, General & Administrative Expenses Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +63.3% | -4.7% | +62.8% | -330.3% | at low |
5 y | 5-year | at high | +994.0% | -4.7% | +820.3% | -9052.8% | at low |
alltime | all time | at high | +2104.7% | -4.7% | +1900.0% | -9052.8% | at low |
Keros Therapeutics Selling, General & Administrative Expenses History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | $9.82 M(-1.4%) | $39.19 M(+1.7%) |
Jun 2024 | - | $9.96 M(-3.4%) | $38.52 M(+3.1%) |
Mar 2024 | - | $10.31 M(+13.2%) | $37.36 M(+7.3%) |
Dec 2023 | $34.83 M(+26.6%) | $9.11 M(-0.5%) | $34.83 M(+6.1%) |
Sep 2023 | - | $9.15 M(+3.9%) | $32.82 M(+7.2%) |
Jun 2023 | - | $8.80 M(+13.2%) | $30.61 M(+4.6%) |
Mar 2023 | - | $7.78 M(+9.7%) | $29.25 M(+6.3%) |
Dec 2022 | $27.52 M(+29.0%) | $7.09 M(+2.2%) | $27.52 M(+4.0%) |
Sep 2022 | - | $6.94 M(-6.8%) | $26.46 M(+6.3%) |
Jun 2022 | - | $7.45 M(+23.1%) | $24.89 M(+7.7%) |
Mar 2022 | - | $6.05 M(+0.2%) | $23.10 M(+8.3%) |
Dec 2021 | $21.33 M | $6.03 M(+12.5%) | $21.33 M(+12.8%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2021 | - | $5.37 M(-5.2%) | $18.91 M(+10.6%) |
Jun 2021 | - | $5.66 M(+32.4%) | $17.10 M(+13.3%) |
Mar 2021 | - | $4.27 M(+18.2%) | $15.09 M(+17.9%) |
Dec 2020 | $12.80 M(+301.9%) | $3.62 M(+1.8%) | $12.80 M(+24.9%) |
Sep 2020 | - | $3.55 M(-2.7%) | $10.25 M(+33.7%) |
Jun 2020 | - | $3.65 M(+84.6%) | $7.67 M(+64.2%) |
Mar 2020 | - | $1.98 M(+85.3%) | $4.67 M(+46.7%) |
Dec 2019 | $3.18 M(+101.5%) | $1.07 M(+9.8%) | $3.18 M(+50.4%) |
Sep 2019 | - | $972.00 K(+48.6%) | $2.12 M(+84.9%) |
Jun 2019 | - | $654.00 K(+33.2%) | $1.15 M(+133.2%) |
Mar 2019 | - | $491.00 K | $491.00 K |
Dec 2018 | $1.58 M | - | - |
FAQ
- What is Keros Therapeutics annual SGA?
- What is the all time high annual SGA for Keros Therapeutics?
- What is Keros Therapeutics annual SGA year-on-year change?
- What is Keros Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Keros Therapeutics?
- What is Keros Therapeutics quarterly SGA year-on-year change?
- What is Keros Therapeutics TTM SGA?
- What is the all time high TTM SGA for Keros Therapeutics?
- What is Keros Therapeutics TTM SGA year-on-year change?
What is Keros Therapeutics annual SGA?
The current annual SGA of KROS is $34.83 M
What is the all time high annual SGA for Keros Therapeutics?
Keros Therapeutics all-time high annual SGA is $34.83 M
What is Keros Therapeutics annual SGA year-on-year change?
Over the past year, KROS annual SGA has changed by +$7.31 M (+26.55%)
What is Keros Therapeutics quarterly SGA?
The current quarterly SGA of KROS is $9.82 M
What is the all time high quarterly SGA for Keros Therapeutics?
Keros Therapeutics all-time high quarterly SGA is $10.31 M
What is Keros Therapeutics quarterly SGA year-on-year change?
Over the past year, KROS quarterly SGA has changed by +$715.00 K (+7.85%)
What is Keros Therapeutics TTM SGA?
The current TTM SGA of KROS is -$1.80 B
What is the all time high TTM SGA for Keros Therapeutics?
Keros Therapeutics all-time high TTM SGA is -$19.65 M
What is Keros Therapeutics TTM SGA year-on-year change?
Over the past year, KROS TTM SGA has changed by -$1.83 B (-5263.11%)